MCID: GLC003
MIFTS: 58

Glucose Intolerance

Categories: Metabolic diseases

Aliases & Classifications for Glucose Intolerance

MalaCards integrated aliases for Glucose Intolerance:

Name: Glucose Intolerance 12 28 51 41 14
Impaired Glucose Tolerance 69
Malabsorption of Glucose 12
Fatty Stool 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10603
ICD10 32 R73.09
MeSH 41 D018149
NCIt 46 C34646
UMLS 69 C0271650

Summaries for Glucose Intolerance

MalaCards based summary : Glucose Intolerance, also known as impaired glucose tolerance, is related to lipodystrophy, familial partial, type 2 and arteries, anomalies of. An important gene associated with Glucose Intolerance is INS (Insulin), and among its related pathways/superpathways are Regulation of lipid metabolism Insulin signaling-generic cascades and Common Cytokine Receptor Gamma-Chain Family Signaling Pathways. The drugs Metformin and Saxagliptin have been mentioned in the context of this disorder. Affiliated tissues include ovary, heart and endothelial, and related phenotypes are adipose tissue and endocrine/exocrine gland

Wikipedia : 72 Impaired glucose tolerance (IGT) is a pre-diabetic state of hyperglycemia that is associated with... more...

Related Diseases for Glucose Intolerance

Diseases related to Glucose Intolerance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 187)
# Related Disease Score Top Affiliating Genes
1 lipodystrophy, familial partial, type 2 31.9 INS LEP
2 arteries, anomalies of 30.2 ADIPOQ CRP INS LEP
3 coronary heart disease 1 30.1 ADIPOQ CRP INS LPL
4 hyperproinsulinemia 30.1 IGFBP1 INS SHBG
5 acromegaly 30.0 GHRL IGF1 IGFBP1 INS
6 hyperinsulinemic hypoglycemia 30.0 GCK INS INSR
7 myocardial infarction 30.0 ADIPOQ CRP GHRL INS RETN
8 apnea, obstructive sleep 29.9 ADIPOQ CRP INS LEP
9 hyperthyroidism 29.8 GHRL INS LEP SHBG
10 turner syndrome 29.8 IGF1 IGFBP1 SHBG
11 hyperandrogenism 29.7 IGF1 IGFBP1 INS INSR SHBG
12 polycystic ovary syndrome 29.7 GHRL IGF1 IGFBP1 INS INSR IRS1
13 coronary artery anomaly 29.7 ADIPOQ CRP INS LPL RETN
14 anovulation 29.7 IGF1 INS LEP SHBG
15 chronic kidney failure 29.6 CRP IGF1 INS LEP
16 fatty liver disease 29.5 ADIPOQ INS INSR LEP LEPR RETN
17 insulinoma 29.5 GCG GCK INS
18 hypoglycemia 29.4 GCG GCK INS INSR
19 insulin-like growth factor i 29.4 IGF1 IGFBP1 INS INSR IRS1 LEP
20 lutheran suppressor, x-linked 29.2 ADIPOQ ADRB3 INS INSR IRS1 LEP
21 gestational diabetes 29.0 ADIPOQ ADRB3 GCK INS INSR IRS1
22 hypertension, essential 28.9 ADIPOQ ADRB3 CRP INS INSR LEP
23 sleep apnea 28.8 ADIPOQ CRP GHRL IGF1 INS LEP
24 hyperglycemia 28.6 ADIPOQ DPP4 GCG GCK IGF1 INS
25 hyperinsulinism 28.6 GCK GHRL IGF1 IGFBP1 INS INSR
26 diabetes mellitus 28.4 ADIPOQ ADRB3 CRP GCG GCK IGF1
27 overnutrition 26.9 ADIPOQ ADRB3 CRP GCG GHRL IGF1
28 body mass index quantitative trait locus 11 25.8 ADIPOQ ADRB3 CRP DPP4 GCG GCK
29 diabetes mellitus, noninsulin-dependent 24.5 ADIPOQ ADRB3 CRP DPP4 GCG GCK
30 steatorrhea 11.2
31 mental retardation, skeletal dysplasia, and abducens palsy 11.1
32 growth hormone insensitivity with immunodeficiency 10.9
33 aromatase deficiency 10.9
34 estrogen resistance 10.9
35 body mass index quantitative trait locus 9 10.7
36 body mass index quantitative trait locus 8 10.7
37 body mass index quantitative trait locus 7 10.7
38 body mass index quantitative trait locus 12 10.7
39 body mass index quantitative trait locus 14 10.7
40 body mass index quantitative trait locus 18 10.7
41 body mass index quantitative trait locus 4 10.7
42 body mass index quantitative trait locus 10 10.7
43 insulin autoimmune syndrome 10.6 INS INSR
44 malignant otitis externa 10.6 CRP INS
45 maturity-onset diabetes of the young, type 2 10.5 GCK INS
46 mixed cell adenoma 10.5 IGF1 IRS1
47 hepatitis 10.4
48 acquired generalized lipodystrophy 10.4 ADIPOQ LEP RETN
49 hyperlipoproteinemia, type v 10.4 INS LPL
50 idiopathic recurrent pericarditis 10.4 ADIPOQ LEP RETN

Graphical network of the top 20 diseases related to Glucose Intolerance:



Diseases related to Glucose Intolerance

Symptoms & Phenotypes for Glucose Intolerance

MGI Mouse Phenotypes related to Glucose Intolerance:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 10.26 IRS1 LPL LEP RETN SLC2A4 LEPR
2 endocrine/exocrine gland MP:0005379 10.22 IRS1 RBP4 LEP SLC2A4 LEPR GHRL
3 homeostasis/metabolism MP:0005376 10.22 LPL IRS1 RBP4 LEP RETN SLC2A4
4 cardiovascular system MP:0005385 10.2 LPL IRS1 RBP4 LEP SLC2A4 LEPR
5 cellular MP:0005384 10.17 LEPR LPL IRS1 RBP4 LEP INSR
6 growth/size/body region MP:0005378 10.15 LPL IRS1 LEP SLC2A4 INSR LEPR
7 immune system MP:0005387 10 IRS1 RETN LEP INSR LEPR IGF1
8 liver/biliary system MP:0005370 9.9 IRS1 LPL LEP RETN SLC2A4 LEPR
9 muscle MP:0005369 9.65 LPL IRS1 RBP4 LEP SLC2A4 LEPR
10 renal/urinary system MP:0005367 9.17 INSR LEPR LEP IGF1 ADIPOQ INS

Drugs & Therapeutics for Glucose Intolerance

Drugs for Glucose Intolerance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 532)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 4091 14219
2
Saxagliptin Approved Phase 4,Phase 3,Phase 2 361442-04-8 11243969
3
Curcumin Approved, Investigational Phase 4 458-37-7 969516
4
Rosiglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 122320-73-4 77999
5
Acarbose Approved, Investigational Phase 4,Phase 3 56180-94-0 441184
6
Benzocaine Approved, Investigational Phase 4,Phase 2 1994-09-7, 94-09-7 2337
7
Amiloride Approved Phase 4 2609-46-3, 2016-88-8 16231
8
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 58-93-5 3639
9
Insulin Glargine Approved Phase 4,Phase 3,Phase 1 160337-95-1
10
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
11
Ethanol Approved Phase 4,Phase 3 64-17-5 702
12
Voglibose Approved, Investigational Phase 4 83480-29-9 444020
13
Nitric Oxide Approved Phase 4,Phase 2,Phase 3,Phase 1 10102-43-9 145068
14
Testosterone Approved, Investigational Phase 4,Phase 3 58-22-0 6013
15
Simvastatin Approved Phase 4,Phase 2,Phase 3 79902-63-9 54454
16
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 5282452 6366718
17
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 1 141758-74-9 15991534
18
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
19
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846
20
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 111025-46-8 4829
21
Hydroxychloroquine Approved Phase 4 118-42-3 3652
22
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
23
Losartan Approved Phase 4,Phase 2 114798-26-4 3961
24
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
25
Nateglinide Approved, Investigational Phase 4,Phase 3 105816-04-4 60026
26
Telmisartan Approved, Investigational Phase 4,Phase 2 144701-48-4 65999
27
Amlodipine Approved Phase 4 88150-42-9 2162
28
Bexarotene Approved, Investigational Phase 4 153559-49-0 82146
29
Copper Approved, Investigational Phase 4 7440-50-8 27099
30
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
31
Budesonide Approved Phase 4 51333-22-3 5281004 63006
32
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
33
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
34
Abacavir Approved, Investigational Phase 4 136470-78-5 441300 65140
35
Lamivudine Approved, Investigational Phase 4,Phase 3 134678-17-4 60825
36
Lopinavir Approved Phase 4 192725-17-0 92727
37
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
38
Zidovudine Approved Phase 4,Phase 3 30516-87-1 35370
39
Trandolapril Approved Phase 4 87679-37-6 5484727
40
Verapamil Approved Phase 4 52-53-9 2520
41
Everolimus Approved Phase 4 159351-69-6 6442177
42
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
43
Sirolimus Approved, Investigational Phase 4 53123-88-9 46835353 6436030 5284616
44
Tacrolimus Approved, Investigational Phase 4,Phase 1,Phase 2 104987-11-3 445643 439492
45
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 1,Phase 2 128794-94-5 5281078
46
Mycophenolic acid Approved Phase 4,Phase 1,Phase 2 24280-93-1 446541
47
Daclizumab Approved, Investigational Phase 4 152923-56-3
48
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
49
Prednisone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Early Phase 1 53-03-2 5865
50
Liraglutide Approved Phase 4,Phase 3,Phase 2,Phase 1 204656-20-2 44147092

Interventional clinical trials:

(show top 50) (show all 1004)

# Name Status NCT ID Phase Drugs
1 Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
2 Curcumin Therapy in Patients With Impaired Glucose Tolerance and Insulin Resistance Unknown status NCT01052025 Phase 4 Curcumin
3 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
4 Effect of Acute Hyperglycemia on Renal Tissue Oxygenation Unknown status NCT02346149 Phase 4
5 Intensity of Exercise and Glucose Metabolism Unknown status NCT01649219 Phase 4
6 Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial) Unknown status NCT00858676 Phase 4 acarbose
7 Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study Unknown status NCT02409238 Phase 4 Metformin
8 Comparison of Single and Combination Diuretics in Low-Renin Hypertension Unknown status NCT02351973 Phase 4 Hydrochlorthiazide;Amiloride;Hydrochlorthiazide and Amiloride
9 Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD) Unknown status NCT01035528 Phase 4 insulin glargine;metformin
10 Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients Unknown status NCT02057523 Phase 4 Acthar
11 Sitagliptin and Brown Adipose Tissue Unknown status NCT02294084 Phase 4 Sitagliptin;placebo
12 Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients Unknown status NCT00135460 Phase 4 nucleoside analogue sparing HAART regimen
13 Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes Completed NCT02700334 Phase 4 Dapagliflozin;Placebo
14 Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT) Completed NCT00301392 Phase 4 Life style interventions plus concomitant use of pitavastatin.
15 Effects of Physical Activity on the Brain in Impaired Glucose Tolerance (IGT) Completed NCT01219231 Phase 4
16 Effects of Antidiabetic Medications on the Postprandial State in Prediabetes Completed NCT02104739 Phase 4 Exenatide;Saxagliptin;Exenatide ER
17 The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes Completed NCT00546728 Phase 4 Exenatide;Metformin
18 Physical Exercise Versus Rosiglitazone in CAD and Prediabetes Completed NCT00675740 Phase 4 rosiglitazone
19 Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes Completed NCT01964703 Phase 4 Rubus occidentalis extract
20 Effects of Vitamin D on Beta Cell Function and Insulin Sensitivity in Pre-diabetes and Diabetes Mellitus Type 2 Completed NCT01497132 Phase 4 Vitamin D3;Placebo
21 Evaluating the Effects of a Diet and Exercise Program in People With Type 2 Diabetes or Prediabetes: (The SHAPE3 Study) Completed NCT00928005 Phase 4
22 Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance Completed NCT00241072 Phase 4 valsartan
23 Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance Completed NCT00108615 Phase 4 Metformin;Pioglitazone;Metformin;Pioglitazone
24 Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes Completed NCT02689765 Phase 4
25 Development of Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes Completed NCT02617693 Phase 4
26 Postmarketing Clinical Study on AO-128 Completed NCT02287402 Phase 4 AO-128
27 Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes Completed NCT01326533 Phase 4 hydroxychloroquine
28 Sitagliptin in Renal Transplant Recipients Completed NCT00740363 Phase 4 sitagliptin;placebo
29 Metformin and Longevity Genes in Prediabetes Completed NCT01765946 Phase 4 Metformin;placebo
30 The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose Completed NCT00673790 Phase 4 Nebivolol;HCTZ;Placebo
31 Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome Completed NCT03122041 Phase 4 Sitagliptin
32 Oral Cholecalciferol in Prevention of Type 2 Diabetes Mellitus Completed NCT01436916 Phase 4 oral cholecalciferol + life style counselling;placebo + life style counselling
33 Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients Completed NCT00319189 Phase 4 Nateglinide
34 Telmisartan and Losartan in Hypertensive IGT Completed NCT00407862 Phase 4 Telmisartan 80 mg;Losartan 50 mg
35 The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes Completed NCT01181986 Phase 4 Exenatide SC;Exenatide IV;Placebo SC;Exendin-9;Placebo IV
36 Acarbose Cardiovascular Evaluation Trial Completed NCT00829660 Phase 4 Acarbose;Matching Placebo
37 Acute Effect of Exenatide on Brain Glucose Metabolism Completed NCT01588418 Phase 4 Exenatide;Placebo
38 Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance Completed NCT00129233 Phase 4 Valsartan;Amlodipine
39 The Effect of Korean Red Ginseng Supplementation on Glucose Control Completed NCT01911663 Phase 4
40 Mechanisms Underlying Metabolic Syndrome in Obesity Completed NCT00579813 Phase 4 Pioglitazone
41 Incretins in Impaired Fasting Glucose Completed NCT00364377 Phase 4 Sitagliptin
42 Beta-cell Function in Glucose Abnormalities and Acute Myocardial Infarction Completed NCT00627744 Phase 4 Sitagliptin
43 The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women Completed NCT00456885 Phase 4 exenatide;Placebo
44 Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM Completed NCT01856907 Phase 4 Sitagliptin-Metformin;Metformin;Placebo pill
45 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
46 Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients Completed NCT02355509 Phase 4 Acarbose;Placebo
47 Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults Completed NCT00352287 Phase 4 Recombinant human growth hormone; pioglitazone
48 Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function Completed NCT00845182 Phase 4 Pioglitazone;Exenatide;Pioglitazone and Exenatide
49 Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma Completed NCT01569724 Phase 4
50 Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation Completed NCT00974272 Phase 4 Exenatide

Search NIH Clinical Center for Glucose Intolerance

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: glucose intolerance

Genetic Tests for Glucose Intolerance

Genetic tests related to Glucose Intolerance:

# Genetic test Affiliating Genes
1 Glucose Intolerance 28

Anatomical Context for Glucose Intolerance

MalaCards organs/tissues related to Glucose Intolerance:

38
Ovary, Heart, Endothelial, Kidney, Testes, Liver, Brain

Publications for Glucose Intolerance

Articles related to Glucose Intolerance:

(show top 50) (show all 745)
# Title Authors Year
1
Tau ablation in mice leads to pancreatic I^ cell dysfunction and glucose intolerance. ( 29401605 )
2018
2
Arsenic exposure induces glucose intolerance and alters global energy metabolism. ( 29118024 )
2018
3
Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice. ( 29404514 )
2018
4
Glucose effectiveness is a critical pathogenic factor leading to the emergence of glucose intolerance and type 2 diabetes mellitus: an ignored hypothesis. ( 29451713 )
2018
5
Circulating B-type natriuretic peptide in women with and without recent gestational diabetes: The impact of current glucose intolerance. ( 29112786 )
2018
6
High-fat diet induces a neurometabolic state characterized by changes in glutamate and N-acetylaspartate pools associated with early glucose intolerance: An in vivo multimodal MRI study. ( 29377412 )
2018
7
Induced Cre-mediated knockdown of Brca1 in skeletal muscle reduces mitochondrial respiration and prevents glucose intolerance in adult mice on a high-fat diet. ( 29401626 )
2018
8
Unclassified hepatocellular adenoma in a middle-aged woman with glucose intolerance. ( 29116626 )
2018
9
Chronic sleep disorder induced by psychophysiological stress induces glucose intolerance without adipose inflammation in mice. ( 29288667 )
2018
10
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain. ( 29364220 )
2018
11
Correction: Intestinal Ralstonia pickettii augments glucose intolerance in obesity. ( 29381738 )
2018
12
Clinical implications of combined glucose intolerance in treatment-naA^ve hypertensive patients. ( 29393699 )
2018
13
Ageing potentiates diet-induced glucose intolerance, I^-cell failure and tissue inflammation through TLR4. ( 29426925 )
2018
14
The Root of Atractylodes macrocephala Koidzumi Prevents Obesity and Glucose Intolerance and Increases Energy Metabolism in Mice. ( 29342124 )
2018
15
Risk of glucose intolerance and gestational diabetes mellitus in relation to maternal habitual snoring during early pregnancy. ( 28926639 )
2017
16
Cytosolic Pellino-1-Mediated K63-Linked Ubiquitination of IRF5 in M1 Macrophages Regulates Glucose Intolerance in Obesity. ( 28746869 )
2017
17
Postpartum glucose intolerance: an updated overview. ( 28808874 )
2017
18
Pregnancy and Subsequent Glucose Intolerance in Women of Childbearing Age: Heeding the Early Warning Signs for Primary Prevention of Cardiovascular Disease in Women. ( 29049465 )
2017
19
Prevalence of glucose intolerance in rheumatoid arthritis patients at a tertiary care centre in Haryana. ( 28751150 )
2017
20
Inhibition of the gut enzyme intestinal alkaline phosphatase may explain how aspartame promotes glucose intolerance and obesity in mice. ( 27997218 )
2017
21
The relationship between bile acid concentration, glucagon-like-peptide 1, fibroblast growth factor 15 and bile acid receptors in rats during progression of glucose intolerance. ( 28946907 )
2017
22
Differences in characteristics of glucose intolerance between patients with NAFLD and chronic hepatitis C as determined by CGMS. ( 28860506 )
2017
23
Cardamom powder supplementation prevents obesity, improves glucose intolerance, inflammation and oxidative stress in liver of high carbohydrate high fat diet induced obese rats. ( 28806968 )
2017
24
<i>Flos Lonicera</i> Combined with Metformin Ameliorates Hepatosteatosis and Glucose Intolerance in Association with Gut Microbiota Modulation. ( 29204141 )
2017
25
Chow fed UC Davis strain female Lepr fatty Zucker rats exhibit mild glucose intolerance, hypertriglyceridemia, and increased urine volume, all reduced by a Brown Norway strain chromosome 1 congenic donor region. ( 29211750 )
2017
26
Royal jelly ameliorates diet-induced obesity and glucose intolerance by promoting brown adipose tissue thermogenesis in mice. ( 28089395 )
2017
27
Banxia-houpu decoction restores glucose intolerance in CUMS rats through improvement of insulin signaling and suppression of NLRP3 inflammasome activation in liver and brain. ( 28782622 )
2017
28
IgG is elevated in obese white adipose tissue but does not induce glucose intolerance via FcI^-receptor or complement. ( 28852207 )
2017
29
Eplerenone prevented obesity-induced inflammasome activation and glucose intolerance. ( 28855315 )
2017
30
Intestinal Ralstonia pickettii augments glucose intolerance in obesity. ( 29166392 )
2017
31
Regulation of hepatic pyruvate dehydrogenase phosphorylation in offspring glucose intolerance induced by intrauterine hyperglycemia. ( 28148899 )
2017
32
Targeting viperin improves diet-induced glucose intolerance but not adipose tissue inflammation. ( 29254175 )
2017
33
Arsenite in drinking water produces glucose intolerance in pregnant rats and their female offspring. ( 28017702 )
2017
34
Hyperhomocysteinemia as a Metabolic Risk Factor for Glucose Intolerance Among High-Risk Groups of Chinese Adults. ( 28591087 )
2017
35
Human Carboxylesterase 2 Reverses Obesity-Induced Diacylglycerol Accumulation and Glucose Intolerance. ( 28099843 )
2017
36
Treatment of sarcopenia and glucose intolerance through mitochondrial activation by 5-aminolevulinic acid. ( 28638045 )
2017
37
Implementing a Reminder System in the Northern Part of Belgium to Stimulate Postpartum Screening for Glucose Intolerance in Women with Gestational Diabetes: The "Sweet Pregnancy" Project. ( 28775742 )
2017
38
Chronic insulin infusion induces reversible glucose intolerance in lean rats yet ameliorates glucose intolerance in obese rats. ( 27871838 )
2017
39
Host-microbiota interaction induces bi-phasic inflammation and glucose intolerance in mice. ( 29107285 )
2017
40
Alantolactone improves palmitate-induced glucose intolerance and inflammation in both lean and obese states in vitro: Adipocyte and adipocyte-macrophage co-culture system. ( 28599253 )
2017
41
Glucose intolerance as the key risk factor for metabolic syndrome. ( 28921923 )
2017
42
Loss of Hepatic Mitochondrial Long-Chain Fatty Acid Oxidation Confers Resistance to Diet-Induced Obesity and Glucose Intolerance. ( 28723568 )
2017
43
The influence of D-chiro-inositol and D-myo-inositol in pregnant women with glucose intolerance. ( 28804631 )
2017
44
Alantolactone Improves Prolonged Exposure of Interleukin-6-Induced Skeletal Muscle Inflammation Associated Glucose Intolerance and Insulin Resistance. ( 28706484 )
2017
45
Curcumin limits weight gain, adipose tissue growth, and glucose intolerance following the cessation of exercise and caloric restriction in rats. ( 28839007 )
2017
46
Exogenous thyroxine improves glucose intolerance in insulin resistant rats. ( 27980001 )
2016
47
Insulin resistance precedes glucose intolerance and hyperleptinaemia in high-fat simple carbohydrate-fed C57BL/6J mice. ( 28042652 )
2016
48
Loss of Nlrp3 Does Not Protect Mice from Western Diet-Induced Adipose Tissue Inflammation and Glucose Intolerance. ( 27583382 )
2016
49
Protective Role for B-1b B Cells and IgM in Obesity-Associated Inflammation, Glucose Intolerance, and Insulin Resistance. ( 26868208 )
2016
50
Adiponectin, C-reactive protein, fibrinogen and tissue plasminogen activator antigen levels among glucose-intolerant women with and without histories of gestational diabetes. ( 25970741 )
2016

Variations for Glucose Intolerance

Expression for Glucose Intolerance

Search GEO for disease gene expression data for Glucose Intolerance.

Pathways for Glucose Intolerance

Pathways related to Glucose Intolerance according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.87 GCK IGF1 INS INSR IRS1 SLC2A4
2
Show member pathways
12.68 ADIPOQ INS INSR IRS1 LEP RBP4
3
Show member pathways
12.48 INS INSR IRS1 LPL SLC2A4
4 12.48 ADIPOQ GCG IGFBP1 INS INSR IRS1
5
Show member pathways
12.45 GCK INS IRS1 LEP LEPR
6
Show member pathways
12.43 IGF1 INS INSR IRS1
7
Show member pathways
12.27 ADRB3 IGF1 INSR IRS1
8
Show member pathways
12.21 DPP4 GCG GHRL IGF1 INS LEP
9
Show member pathways
12.19 INS INSR IRS1 LEP SLC2A4
10
Show member pathways
12.17 ADIPOQ IGF1 INS INSR IRS1 LEP
11
Show member pathways
12.12 ADIPOQ IGF1 INS INSR IRS1
12
Show member pathways
12.05 IGF1 INS INSR IRS1 SLC2A4
13
Show member pathways
11.91 INS INSR IRS1 SLC2A4
14 11.83 IGF1 INS INSR
15 11.78 ADIPOQ IGF1 INS LEP LPL SLC2A4
16
Show member pathways
11.72 ADIPOQ GCK INS INSR IRS1 SLC2A4
17 11.69 INS LPL RBP4
18 11.67 ADIPOQ IRS1 LEP LEPR SLC2A4
19 11.64 INS INSR IRS1
20 11.63 GCK IGFBP1 LEP
21 11.57 ADRB3 INS INSR IRS1
22
Show member pathways
11.56 DPP4 GCG LEP
23 11.54 IRS1 LEP LEPR SLC2A4
24 11.5 IGF1 INS INSR
25 11.47 INS INSR IRS1 LEP LEPR
26 11.44 GCK IGFBP1 INS
27 11.42 INS INSR IRS1
28 11.36 IGF1 INS INSR IRS1
29 11.35 ADIPOQ IGF1 INS IRS1 LEP LPL
30
Show member pathways
11.24 CRP LEP LEPR
31 11.22 INS INSR SLC2A4
32
Show member pathways
10.95 INSR IRS1 SLC2A4
33 10.86 INS SLC2A4
34 10.7 ADIPOQ INSR IRS1 LEP SLC2A4

GO Terms for Glucose Intolerance

Cellular components related to Glucose Intolerance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 ADIPOQ CRP GCG GHRL IGF1 IGFBP1
2 endoplasmic reticulum lumen GO:0005788 9.56 GCG GHRL IGFBP1 INS
3 extracellular region GO:0005576 9.47 ADIPOQ CRP DPP4 GCG GHRL IGF1
4 insulin receptor complex GO:0005899 9.16 INSR IRS1

Biological processes related to Glucose Intolerance according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.98 ADIPOQ GCG GHRL IGF1 INS LEP
2 carbohydrate metabolic process GO:0005975 9.93 ADRB3 GCK INS INSR SLC2A4
3 positive regulation of protein kinase B signaling GO:0051897 9.91 INS INSR IRS1 LEP
4 response to ethanol GO:0045471 9.88 ADIPOQ LEP RBP4 SLC2A4
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.85 ADIPOQ IGF1 INS
6 response to insulin GO:0032868 9.84 IRS1 LEP RETN
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.83 IGF1 INS LEP
8 insulin receptor signaling pathway GO:0008286 9.83 IGFBP1 INS INSR IRS1
9 response to nutrient levels GO:0031667 9.81 ADIPOQ GHRL LEP
10 regulation of insulin secretion GO:0050796 9.8 DPP4 GCG GCK LEP
11 positive regulation of MAPK cascade GO:0043410 9.8 ADRB3 IGF1 INS INSR LEP
12 positive regulation of insulin secretion GO:0032024 9.78 GCK GHRL RBP4
13 positive regulation of DNA replication GO:0045740 9.77 IGF1 INS INSR
14 cellular response to insulin stimulus GO:0032869 9.77 ADIPOQ GCK INSR IRS1 SLC2A4
15 activation of protein kinase B activity GO:0032148 9.76 IGF1 INS INSR
16 brown fat cell differentiation GO:0050873 9.74 ADIPOQ ADRB3 SLC2A4
17 positive regulation of mitotic nuclear division GO:0045840 9.73 IGF1 INS INSR
18 glucose metabolic process GO:0006006 9.72 ADIPOQ GCK GHRL INS LEP
19 positive regulation of cellular protein metabolic process GO:0032270 9.69 ADIPOQ INS
20 positive regulation of glycolytic process GO:0045821 9.69 IGF1 INS INSR
21 insulin-like growth factor receptor signaling pathway GO:0048009 9.68 IGF1 IRS1
22 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.68 ADIPOQ CRP
23 sexual reproduction GO:0019953 9.68 LEP LEPR
24 negative regulation of blood vessel diameter GO:0097756 9.67 CRP INS
25 cellular response to leptin stimulus GO:0044320 9.67 GCK LEP
26 adult feeding behavior GO:0008343 9.67 GHRL LEP
27 negative regulation of lipid storage GO:0010888 9.66 CRP LEP
28 leptin-mediated signaling pathway GO:0033210 9.65 LEP LEPR
29 regulation of bone remodeling GO:0046850 9.65 LEP LEPR
30 energy reserve metabolic process GO:0006112 9.65 ADRB3 LEP LEPR
31 negative regulation of feeding behavior GO:2000252 9.64 INS RETN
32 positive regulation of respiratory burst GO:0060267 9.63 INS INSR
33 neuron projection maintenance GO:1990535 9.63 INS INSR
34 positive regulation of insulin receptor signaling pathway GO:0046628 9.63 INS IRS1 LEP
35 positive regulation of developmental growth GO:0048639 9.62 INSR LEP
36 bone mineralization involved in bone maturation GO:0035630 9.62 IGF1 LEP
37 negative regulation of gluconeogenesis GO:0045721 9.56 ADIPOQ GCK INS LEPR
38 bone growth GO:0098868 9.55 LEP LEPR
39 positive regulation of glucose import GO:0046326 9.55 ADIPOQ IGF1 INS INSR IRS1
40 positive regulation of glycogen biosynthetic process GO:0045725 9.35 GCK IGF1 INS INSR IRS1
41 glucose homeostasis GO:0042593 9.28 ADIPOQ GCK INS INSR IRS1 LEP
42 positive regulation of cell proliferation GO:0008284 10.07 DPP4 IGF1 INS INSR IRS1 LEP

Molecular functions related to Glucose Intolerance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 9.63 ADIPOQ DPP4 GCG IGFBP1 LEP LPL
2 insulin receptor binding GO:0005158 9.43 IGF1 INS IRS1
3 insulin-like growth factor I binding GO:0031994 9.4 IGFBP1 INSR
4 insulin-like growth factor II binding GO:0031995 9.32 IGFBP1 INSR
5 insulin-like growth factor receptor binding GO:0005159 9.26 IGF1 INS INSR IRS1
6 hormone activity GO:0005179 9.17 ADIPOQ GCG GHRL IGF1 INS LEP
7 protein binding GO:0005515 10.3 ADIPOQ ADRB3 CRP DPP4 GCG GCK

Sources for Glucose Intolerance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....